Results 31 to 40 of about 453,809 (210)

Moving forward through the in silico modeling of tuberculosis: a further step with UISS-TB

BMC Bioinformatics, 2020
Background In 2018, about 10 million people were found infected by tuberculosis, with approximately 1.2 million deaths worldwide. Despite these numbers have been relatively stable in recent years, tuberculosis is still considered one of the top 10 ...
Giulia Russo, Giuseppe Sgroi, Giuseppe Alessandro Parasiliti Palumbo, Marzio Pennisi, Miguel A. Juarez, Pere-Joan Cardona, Santo Motta, Kenneth B. Walker, Epifanio Fichera, Marco Viceconti, Francesco Pappalardo   +10 more
doaj   +1 more source

Structural modification of a novel inhibitor for mycobacterium enoyl-acyl carrier protein reductase assisted by In silico structure-based drug screening

International Journal of Mycobacteriology, 2020
Background: Mycobacterium tuberculosis enoyl-acyl carrier protein reductase (mtInhA) is involved in the biosynthesis of mycolic acids, a major component of mycobacterial cell walls, and has been targeted in the development of anti-tuberculosis (TB) drugs.
Junichi Taira, Toshiki Nagano, Mitsuru Kitamura, Miho Yamaguchi, Hiroshi Sakamoto, Shunsuke Aoki   +5 more
doaj   +1 more source

In silico study of the interaction of phenazines with tuberculostatic activity with known molecular targets of Mycobacterium tuberculosis

Results in Chemistry, 2023
Phenazines derived from β-lapachone had tuberculostatic activity reported in the literature. However, very little is known about their mechanism of action or molecular targets.
Raphael S.F. Silva, Joyce S.F.D. de Almeida, Tanos C.C. França   +2 more
doaj   +1 more source

Gut Microbiota‐Derived Indole‐3‐Acetaldehyde Contributes to the Disease‐Alleviating Effects of Kurarinone in Experimental Autoimmune Encephalomyelitis

Advanced Science, EarlyView.
Kurarinone ameliorates EAE via the gut microbiota‐indole‐3‐acetaldehyde‐AhR axis. Kurarinone reshapes gut microbiota and increases Akkermansia muciniphila, which promotes intestinal indole‐3‐acetaldehyde production. Indole‐3‐acetaldehyde crosses the intestinal barrier, activates AhR in CD4+ T cells, upregulates SOCS1/3, inhibits JAK2 and STAT3/4 ...
Xinyan Han, Jiaqi Ding, Zonghao Pan, Weitai He, Xue Kang, Cong Zhao, Yi Li, Di Wu, Hongzeng Li, Kaixi Ren, Jiaji Lin, Jun Guo   +11 more
wiley   +1 more source

Potential Anti-Mycobacterium tuberculosis Activity of Plant Secondary Metabolites: Insight with Molecular Docking Interactions

Antioxidants, 2021
Tuberculosis (TB) is a recurrent and progressive disease, with high mortality rates worldwide. The drug-resistance phenomenon of Mycobacterium tuberculosis is a major obstruction of allelopathy treatment.
Manu Kumar, Sandeep Kumar Singh, Prem Pratap Singh, Vipin Kumar Singh, Avinash Chandra Rai, Akhileshwar Kumar Srivastava, Livleen Shukla, Mahipal Singh Kesawat, Atul Kumar Jaiswal, Sang-Min Chung, Ajay Kumar   +10 more
doaj   +1 more source

Homocitrullinated Peptides Drive Pro‐Inflammatory T Cell Responses in a Humanized Mouse Model of Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Anti‐homocitrullinated protein/peptide antibodies are specific to rheumatoid arthritis (RA) and predictive of worse prognosis, suggesting a pathogenic role for autoreactivity to homocitrullinated peptides (HomoCitP). However, T cell responses to HomoCitP remain largely unexplored.
Sofya Ulanova, Jaspreet Kaur, Gabrielle Buckley, S. M. Mansour Haeryfar, Lisa Cameron, Ewa Cairns, Lillian Barra   +6 more
wiley   +1 more source

Predicting the artificial immunity induced by RUTI® vaccine against tuberculosis using universal immune system simulator (UISS)

BMC Bioinformatics, 2019
Background Tuberculosis (TB) represents a worldwide cause of mortality (it infects one third of the world’s population) affecting mostly developing countries, including India, and recently also developed ones due to the increased mobility of the world ...
Marzio Pennisi, Giulia Russo, Giuseppe Sgroi, Angela Bonaccorso, Giuseppe Alessandro Parasiliti Palumbo, Epifanio Fichera, Dipendra Kumar Mitra, Kenneth B. Walker, Pere-Joan Cardona, Merce Amat, Marco Viceconti, Francesco Pappalardo   +11 more
doaj   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Pre-clinical evaluation of quinoxaline-derived chalcones in tuberculosis. [PDF]

PLoS ONE, 2018
New effective compounds for tuberculosis treatment are needed. This study evaluated the effects of a series of quinoxaline-derived chalcones against laboratorial strains and clinical isolates of M. tuberculosis.
Thaís C Muradás, Bruno L Abbadi, Anne D Villela, Fernanda S Macchi, Pedro F Bergo, Talita F de Freitas, Nathalia D M Sperotto, Luis F S M Timmers, Osmar Norberto de Souza, Jaqueline N Picada, Jean Fachini, Juliana Bondan da Silva, Nayara C P de Albuquerque, Maísa D Habenschus, Daniel B Carrão, Bruno A Rocha, Fernando Barbosa Junior, Anderson R M de Oliveira, Alessandra Mascarello, Patrícia Neuenfeldf, Ricardo J Nunes, Héctor R Morbidoni, Maria M Campos, Luiz A Basso, Valnês S Rodrigues-Junior   +24 more
doaj   +1 more source

Analysis of Carbohydrates and Glycoconjugates by Matrix‐Assisted Laser Desorption/Ionization Mass Spectrometry: An Update for 2023–2024

Mass Spectrometry Reviews, EarlyView.
ABSTRACT The use of MALDI mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this comprehensive review is the twelfth update of the original article published in 1999 and brings coverage of the literature to the end of 2024.
David J. Harvey
wiley   +1 more source